Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Motugivatrep may be well tolerated at 1 year
Patients receiving the treatment alone or alongside existing therapies showed sustained improvements in dry eye symptoms and ocular surface findings in a 52-week phase 3 study.
In this 52-week, open-label, single-arm phase 3 study, 162 adults with dry eye disease received motugivatrep 0.3% 4 times daily alone or with existing therapies.
2
Treatment-emergent adverse events occurred in 45% of patients, and treatment-related adverse events occurred in 15%; most treatment-related events were mild.
3
No severe or serious treatment-related adverse events or deaths were reported, and 3 serious adverse events were considered unrelated to treatment.
4
Patient-reported symptoms and corneal staining improved during treatment, while tear break-up time increased; tear secretion decreased from baseline.
5
The uncontrolled, unmasked design and enrollment of mostly Japanese patients with relatively mild corneal staining limit attribution of improvements and generalizability.
